An Integrated Investigation of Sulfotransferases (SULTs) in Hepatocellular Carcinoma and Identification of the Role of SULT2A1 on Stemness

Overview

Journal Apoptosis

Publisher Springer

Date 2024 Feb 27

PMID 38411862

Authors

Hao Peng

Kun Feng

Weilu Jia

Yunxin Li

Qingpeng Lv

Yewei Zhang

Affiliations

Soon will be listed here.

Abstract

The cytosolic sulfotransferases (SULTs) are phase II conjugating enzymes, which are widely expressed in the liver and mainly mediate the sulfation of numerous xenobiotics and endogenous compounds. However, the role of various SULTs genes has not been reported in hepatocellular carcinoma (HCC). This study aims to analyze the expression and potential functional roles of SULTs genes in HCC and to identify the role of SULT2A1 in HCC stemness as well as the possible mechanism. We found that all of the 12 SULTs genes were differentially expressed in HCC. Moreover, clinicopathological features and survival rates were also investigated. Multivariate regression analysis showed that SULT2A1 and SULT1C2 could be used as independent prognostic factors in HCC. SULT1C4, SULT1E1, and SULT2A1 were significantly associated with immune infiltration. SULT2A1 deficiency in HCC promoted chemotherapy resistance and stemness maintenance. Mechanistically, silencing of SULT2A1 activated the AKT signaling pathway, on the one hand, promoted the expression of downstream stemness gene c-Myc, on the other hand, facilitated the NRF2 expression to reduce the accumulation of ROS, and jointly increased HCC stemness. Moreover, knockdown NR1I3 was involved in the transcriptional regulation of SULT2A1 in stemness maintenance. In addition, SULT2A1 knockdown HCC cells promoted the proliferation and activation of hepatic stellate cells (HSCs), thereby exerting a potential stroma remodeling effect. Our study revealed the expression and role of SULTs genes in HCC and identified the contribution of SULT2A1 to the initiation and progression of HCC.

References

Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

Pinter M, Jain R, Duda D . The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol. 2020; 7(1):113-123. PMC: 8265820. DOI: 10.1001/jamaoncol.2020.3381. View

Yang J, Nakamura I, Roberts L . The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2010; 21(1):35-43. PMC: 3050428. DOI: 10.1016/j.semcancer.2010.10.007. View

Xie Y, Xie W . The Role of Sulfotransferases in Liver Diseases. Drug Metab Dispos. 2020; 48(9):742-749. PMC: 7469250. DOI: 10.1124/dmd.120.000074. View

Coughtrie M . Function and organization of the human cytosolic sulfotransferase (SULT) family. Chem Biol Interact. 2016; 259(Pt A):2-7. DOI: 10.1016/j.cbi.2016.05.005. View

Shi L, Shen W, Davis M, Kong K, Vu P, Saha S . SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers. Nat Cancer. 2023; 4(3):365-381. PMC: 11090616. DOI: 10.1038/s43018-023-00523-0. View

Jiang L, Xu F, Li C, Liu T, Zhao Q, Liu Y . Sulfotransferase 1C2 promotes hepatocellular carcinoma progression by enhancing glycolysis and fatty acid metabolism. Cancer Med. 2023; 12(9):10738-10754. PMC: 10225225. DOI: 10.1002/cam4.5759. View

He T, Tao B, Yi C, Zhang C, Zhang P, Shao W . 27-Hydroxycholesterol promotes metastasis by SULT2A1-dependent alteration in hepatocellular carcinoma. Cancer Sci. 2022; 113(8):2575-2589. PMC: 9357618. DOI: 10.1111/cas.15435. View

Yang X, Xu Y, Guo F, Ning Y, Zhi X, Yin L . Hydroxysteroid sulfotransferase SULT2B1b promotes hepatocellular carcinoma cells proliferation in vitro and in vivo. PLoS One. 2013; 8(4):e60853. PMC: 3623875. DOI: 10.1371/journal.pone.0060853. View

10.

Yang X, Du X, Sun L, Zhao X, Zhu J, Li G . SULT2B1b promotes epithelial-mesenchymal transition through activation of the β-catenin/MMP7 pathway in hepatocytes. Biochem Biophys Res Commun. 2019; 510(4):495-500. DOI: 10.1016/j.bbrc.2019.01.034. View

11.

Wang S, Wang R, Xu N, Wei X, Yang Y, Lian Z . SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment. Hepatology. 2023; 78(4):1064-1078. DOI: 10.1097/HEP.0000000000000025. View

12.

Chiba T, Zheng Y, Kita K, Yokosuka O, Saisho H, Onodera M . Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology. 2007; 133(3):937-50. DOI: 10.1053/j.gastro.2007.06.016. View

13.

Kim H, Haraguchi N, Ishii H, Ohkuma M, Okano M, Mimori K . Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Ann Surg Oncol. 2011; 19 Suppl 3:S539-48. DOI: 10.1245/s10434-011-2040-5. View

14.

Kahroba H, Shirmohamadi M, Hejazi M, Samadi N . The Role of Nrf2 signaling in cancer stem cells: From stemness and self-renewal to tumorigenesis and chemoresistance. Life Sci. 2019; 239:116986. DOI: 10.1016/j.lfs.2019.116986. View

15.

Noman A, Parag R, Rashid M, Islam S, Rahman M, Chowdhury A . Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation. Cell Death Dis. 2020; 11(8):663. PMC: 7438524. DOI: 10.1038/s41419-020-02907-x. View

16.

Ryoo I, Choi B, Ku S, Kwak M . High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance. Redox Biol. 2018; 17:246-258. PMC: 6006726. DOI: 10.1016/j.redox.2018.04.015. View

17.

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

18.

Asplund A, Edqvist P, Schwenk J, Ponten F . Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research. Proteomics. 2012; 12(13):2067-77. DOI: 10.1002/pmic.201100504. View

19.

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

20.

Lanczky A, Gyorffy B . Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J Med Internet Res. 2021; 23(7):e27633. PMC: 8367126. DOI: 10.2196/27633. View